MAP2K1 and meningioma: Based on our results, demonstrating Raf/MEK/ERK activation in response to MLN3651, we hypothesised that a combination of MLN3651 and the MEK1/2 inhibitor, selumetinib, may have therapeutic potential in Merlin-deficient meningioma.